Sponsor:
Pia Wintermark
Code:
NCT06098833
Conditions
Neonatal Encephalopathy
Eligibility Criteria
Sex: All
Age: 0
Healthy Volunteers: Not accepted
Interventions
Sildenafil
Ora-Blend
Brief summary:
Conditions
Neonatal Encephalopathy
Study ID
NCT06098833
Start date
Jul 1, 2024
Status verified date
Sep, 2026
Completion date
Oct, 2031
Anticipated
Primary completion date
Oct, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 0
Healthy Volunteers: Not accepted
Enrollment
60 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
active comparator: Sildenafil
placebo comparator: Ora-Blend
Interventions
Sildenafil
Ora-Blend
Primary outcome measure
Central contacts
Locations
Children's Hospital Colorado
Recruiting
Denver, Colorado, United States, 80045
Contacts
Principal Investigator:
Sunah Hwang, MD, PhD, MPH/MSPH
Montreal Children's Hospital
Recruiting
Montreal, Quebec, Canada, H3C 0T3
Contacts
Principal Investigator:
Pia Wintermark, MD
Centre Hospitalier Universitaire Sainte-Justine
Recruiting
Montreal, Quebec, Canada, H3T 1C5
Contacts
Principal Investigator:
Anie Lapointe, MD
Sponsor
Pia Wintermark
Last update posted
Sep 17, 2026
Last verified
Sep, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Pia Wintermark on 2026-09-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.